Merck & Co., Inc: Infections trials
The registry lists 13 Infections studies with Merck & Co., Inc as lead sponsor. 1 are open to participants now and 7 have results posted.
Phase 2 7Phase 3 4Phase 4 2No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)RecruitingNCT07266831Phase 2/3
- Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)CompletedNCT03643952Phase 2Results posted
- V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)CompletedNCT03486834Phase 2Results posted
- Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096)CompletedNCT03111108Phase 4Results posted
- Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium for the Treatment of Diabetic Foot Infections in Chinese Adults (MK-0826-061)CompletedNCT01370616Phase 3Results posted
- Efficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056)CompletedNCT01254344Phase 3Results posted
- GARDASIL Reexamination Study (V501-059)CompletedNCT01062074Results posted
- Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure InfectionsCompletedNCT00761215Phase 2Results posted
- A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)Active, not recruitingNCT06891066Phase 2
- A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)WithdrawnNCT05130086Phase 2
- A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)CompletedNCT00445094Phase 4
- To Evaluate the Treatment Effect of an Anti-Infective Agent for Different Kinds of Infections (0826-052)CompletedNCT00398099Phase 3
- An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections (0826-038)CompletedNCT00092170Phase 2